FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL											
OMB Number:	3235-0287										
Estimated average burden											
hours per response:	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last) C/O KIN	John F. (Fi	RMACEUTICA			Susuer Name and Ticker or Trading Symbol Kiniksa Pharmaceuticals, Ltd. [KNSA] Date of Earliest Transaction (Month/Day/Year) 09/02/2021								(Ch	Relationship of Reporting Person(s) to Issuer eck all applicable) Director 10% Owner X Officer (give title below) Chief Medical Officer				
(Street) HAMILT	TON D		HM11 (Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable te) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D.				ction 2A. Deemed Execution Date,		3. Transacti Code (Ins 8)	ion str.	4. Securit Disposed 5)	ties Acquire I Of (D) (Ins (A) or (D)	ed (A) or tr. 3, 4 and Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Seneficial Ownership Instr. 4)			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	(e.g., pt		tansaction ode (Instr. 5. Number of Derivative				onvertil	7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
Share Option	\$12.97	09/02/2021			ode \	v	(A) 41,400	(D)	Date Exercisable	Da	expiration ate	Title Class A Common Shares	Number of Shares 41,400	\$0	41,400		D	
Restricted Share Units	(2)	09/02/2021			A		6,900		(3)		(3)	Class A Common Shares	6,900	\$0	6,900		D	

Explanation of Responses:

- 1. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021.
- 2. Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer.
- 3. The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.

/s/ Madelyn Zeylikman,

Attorney-in-Fact for John F. 09/07/2021

Paolini

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.